Literature DB >> 24348095

Early Detection of Huntington Disease.

Jane S Paulsen1.   

Abstract

Huntington disease (HD) is a devastating illness, although its autosomal dominant genetic transmission allows a unique opportunity to study apparently healthy individuals before manifest disease. Attempts to study early disease are not unique in neurology (e.g., Mild Cognitive Impairment, Vascular Cognitive Impairment), but studying otherwise-healthy appearing individuals who will go on with nearly 99% certainty to manifest the symptoms of brain disease does provide distinct but valuable information about the true natural history of the disease. The field has witnessed an explosion of research examining possible early indicators of HD during what is now referred to as the "prodrome" of HD. A NIH study in its ninth year (PREDICT-HD) has offered a glimpse into the transition from an apparently healthy state to an obviously diseased state, and can serve as a model for many other genetic diseases, both neurological and non-neurological.

Entities:  

Keywords:  Huntington disease; biomarkers; clinical endpoints; clinical trials; detection; diagnosis; prevention

Year:  2010        PMID: 24348095      PMCID: PMC3860286          DOI: 10.2217/fnl.09.78

Source DB:  PubMed          Journal:  Future Neurol        ISSN: 1479-6708


  121 in total

1.  Neuroprotection for Parkinson's disease: prospects and promises.

Authors:  C Warren Olanow; Anthony H V Schapira; Yves Agid
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

2.  Neural bases of dysphoria in early Huntington's disease.

Authors:  Sergio Paradiso; Beth M Turner; Jane S Paulsen; Ricardo Jorge; Laura L Boles Ponto; Robert G Robinson
Journal:  Psychiatry Res       Date:  2008-01-15       Impact factor: 3.222

3.  Huntington's disease progression. PET and clinical observations.

Authors:  T C Andrews; R A Weeks; N Turjanski; R N Gunn; L H Watkins; B Sahakian; J R Hodges; A E Rosser; N W Wood; D J Brooks
Journal:  Brain       Date:  1999-12       Impact factor: 13.501

4.  Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study.

Authors:  C M Kipps; A J Duggins; N Mahant; L Gomes; J Ashburner; E A McCusker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

5.  Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study.

Authors:  Sarah A J Reading; Michael A Yassa; Arnold Bakker; Adam C Dziorny; Lisa M Gourley; Venu Yallapragada; Adam Rosenblatt; Russell L Margolis; Elizabeth H Aylward; Jason Brandt; Susumu Mori; Peter van Zijl; Susan S Bassett; Christopher A Ross
Journal:  Psychiatry Res       Date:  2005-09-30       Impact factor: 3.222

6.  Random number generation in patients with symptomatic and presymptomatic Huntington's disease.

Authors:  Aileen K Ho; Barbara J Sahakian; Trevor W Robbins; Roger A Barker
Journal:  Cogn Behav Neurol       Date:  2004-12       Impact factor: 1.600

7.  Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.

Authors:  Kevin Duff; Leigh J Beglinger; Margaret E O'Rourke; Peg Nopoulos; Henry L Paulson; Jane S Paulsen
Journal:  Ann Clin Psychiatry       Date:  2008 Jan-Mar       Impact factor: 1.567

Review 8.  Psychopathology in verified Huntington's disease gene carriers.

Authors:  E van Duijn; E M Kingma; R C van der Mast
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2007       Impact factor: 2.198

9.  Cognitive changes in asymptomatic carriers of the Huntington disease mutation gene.

Authors:  C Verny; P Allain; A Prudean; M-C Malinge; B Gohier; C Scherer; D Bonneau; F Dubas; D Le Gall
Journal:  Eur J Neurol       Date:  2007-10-17       Impact factor: 6.089

Review 10.  Therapeutic interventions for disease progression in Huntington's disease.

Authors:  Tiago Mestre; Joaquim Ferreira; Miguel M Coelho; Mário Rosa; Cristina Sampaio
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08
View more
  17 in total

1.  Moving toward a gene therapy for Huntington's disease.

Authors:  J C Glorioso; J B Cohen; D L Carlisle; I Munoz-Sanjuan; R M Friedlander
Journal:  Gene Ther       Date:  2015-12       Impact factor: 5.250

2.  New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system).

Authors:  N E Carlozzi; N R Downing; M K McCormack; S G Schilling; J S Perlmutter; E A Hahn; J S Lai; S Frank; K A Quaid; J S Paulsen; D Cella; S M Goodnight; J A Miner; M A Nance
Journal:  Qual Life Res       Date:  2016-07-08       Impact factor: 4.147

3.  Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Authors:  Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready
Journal:  J Huntingtons Dis       Date:  2019

4.  Agreement between clinician-rated versus patient-reported outcomes in Huntington disease.

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Joel S Perlmutter; Kelvin L Chou; Julie C Stout; Jane S Paulsen; Michael K McCormack; David Cella; Martha A Nance; Jin-Shei Lai; Praveen Dayalu
Journal:  J Neurol       Date:  2018-04-23       Impact factor: 4.849

5.  The Confluence of Psychiatric Symptoms and Neurodegenerative Disease: Impact on Genetic Counseling.

Authors:  Jill S Goldman; Edward D Huey; Deborah Z Thorne
Journal:  J Genet Couns       Date:  2016-12-24       Impact factor: 2.537

6.  Suicidal Ideation Assessment in Individuals with Premanifest and Manifest Huntington Disease.

Authors:  Melissa Wesson; Nicholas R Boileau; Joel S Perlmutter; Jane S Paulsen; Stacey K Barton; Michael K McCormack; Noelle E Carlozzi
Journal:  J Huntingtons Dis       Date:  2018

7.  End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning.

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Jane S Paulsen; Joel S Perlmutter; Jin-Shei Lai; Elizabeth A Hahn; Michael K McCormack; Martha A Nance; David Cella; Stacey K Barton; Nancy R Downing
Journal:  J Neurol       Date:  2019-06-12       Impact factor: 4.849

8.  HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).

Authors:  N E Carlozzi; S G Schilling; J-S Lai; J S Paulsen; E A Hahn; J S Perlmutter; C A Ross; N R Downing; A L Kratz; M K McCormack; M A Nance; K A Quaid; J C Stout; R C Gershon; R E Ready; J A Miner; S K Barton; S L Perlman; S M Rao; S Frank; I Shoulson; H Marin; M D Geschwind; P Dayalu; S M Goodnight; D Cella
Journal:  Qual Life Res       Date:  2016-08-13       Impact factor: 4.147

9.  Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?

Authors:  N E Carlozzi; S Schilling; A L Kratz; J S Paulsen; S Frank; J C Stout
Journal:  Qual Life Res       Date:  2018-06-16       Impact factor: 4.147

10.  Apathy Is Related to Cognitive Control and Striatum Volumes in Prodromal Huntington's Disease.

Authors:  Maria B Misiura; Jennifer Ciarochi; Jatin Vaidya; Jeremy Bockholt; Hans J Johnson; Vince D Calhoun; Jane S Paulsen; Jessica A Turner
Journal:  J Int Neuropsychol Soc       Date:  2019-02-26       Impact factor: 2.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.